Stockreport

Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)

Alexion Pharmaceuticals, Inc  (ALXN) 
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.alexion.com/investor-relations
PDF – European Commission decision anticipated in June 2020 –– If approved, ULTOMIRIS has the potential to become the new standard of care in Europe for the treatment of aty [Read more]